News Breaks |
|
|
| April 30, 2012 |
| 09:00 EDT |  | ARII, KALU, CERN, EME, DG, PPG, BSYBY, KFT, IDIX, HMSY, CHK, CMP, CPN, AZN, MDT | On The Fly: Analysts Upgrade Summary
Today's noteworthy upgrades include: American Railcar (ARII) upgraded to Neutral from Sell at UBS...AstraZeneca (AZN) upgraded to Buy from Hold at Jefferies and to Neutral from Underweight at JPMorgan...Calpine (CPN) upgraded to Buy from Hold at Jefferies...Chesapeake (CHK) upgraded to Outperform from Market Perform at BMO Capital...Compass Minerals (CMP) upgraded to Buy from Hold at KeyBanc...HMS Holdings (HMSY) upgraded to Buy from Hold at Jefferies...Idenix (IDIX) upgraded to Market Perform from Underperform at JMP Securities...Kraft Foods (KFT) upgraded to Overweight from Neutral at JPMorgan...British Sky Broadcasting (BSYBY) upgraded to Buy from Neutral at Citigroup...PPG Industries (PPG) upgraded to Outperform from Neutral at Credit Suisse...Dollar General (DG) upgraded to Strong Buy from Outperform at Raymond James...EMCOR Group (EME) upgraded to Buy from Hold at Stifel Nicolaus...Cerner (CERN) upgraded to Outperform from Market Perform at Raymond James...Kaiser Aluminum (KALU) upgraded to Buy from Hold at Dahlman Rose...Medtronic (MDT) upgraded to Buy from Neutral at Lazard Capital. |
|
|
News For ARII;AZN;CPN;CMP;CHK;HMSY;IDIX;KFT;BSYBY;PPG;DG;EME;CERN;KALU;MDT From The Last 14 Days Check below for free stories on ARII;AZN;CPN;CMP;CHK;HMSY;IDIX;KFT;BSYBY;PPG;DG;EME;CERN;KALU;MDT the last two weeks. |
|
|
| May 24, 2013 |
| 08:22 EDT |  | AZN | Leerink's biotech analysts hold an analyst/industry conference call
 Subscribe for More Information |
|
| May 23, 2013 |
| 09:31 EDT | | PPG | PPG Industries management to meet with Deutsche Bank
Subscribe for More Information |
|
| 06:03 EDT |  | CHK | Chesapeake implied volatility at lower end of index mean range
Subscribe for More Information |
|
| 05:40 EDT |  | MDT | Medtronic CoreValue system gains CE mark for transcatheter VIV procedures
Subscribe for More Information |
|
| 05:38 EDT | | MDT | Medtronic's In.Pact Falcon yields positive outcomes in small coronary arteries
Subscribe for More Information |
|
| May 22, 2013 |
| 10:00 EDT | | CHK | On The Fly: Analyst Upgrade Summary
Subscribe for More Information |
|
| 09:01 EDT | | AZN | Par Pharmaceutical begins shipment of generic Atacand
Subscribe for More Information |
|
| 07:48 EDT | | MDT | FDA Orthopaedic and Rehabilitation Devices Panel to hold a meeting
Subscribe for More Information |
|
| 07:30 EDT | | CHK | UBS to host a conference
Subscribe for More Information |
|
| 07:24 EDT | | CHK | Chesapeake upgraded to Positive from Neutral at Susquehanna
Susquehanna upgraded Chesapeake based on increased oil and gas forecasts and re-branding initiatives by new CEO Doug Lawler. Price target raised to $26 from $23. |
| |
| May 21, 2013 |
| 13:02 EDT | | MDT | Medtronic announces CE Mark for CapSureFix Novus
Medtronic announced CE Mark and launch of its CapSureFix Novus 5076 Lead, which is now approved in the EU for use in an MRI environment when paired with a Medtronic MR-Conditional pacemaker. The lead has not been approved for that use in the U.S. |
|
| 11:38 EDT | | MDT | High option volume stocks: KOS MWE HGG SOL MDT
|
|
| 09:29 EDT | | AZN | AstraZeneca says Phase III studies of Naloxegol met primary, secondary endpoints
AstraZeneca (AZN) presented the results of two pivotal Phase III studies of naloxegol showing the 25 mg dose of the investigational drug met its primary and secondary endpoints for efficacy and showed a safety profile consistent with previous studies. Data was presented at the Digestive Disease Week meeting in Orlando, Florida. The primary endpoint in both trials was percentage of OIC responders, versus placebo, over 12 weeks of treatment. The secondary endpoints included the 12-week response rate in a laxative inadequate response population, the median time to first spontaneous bowel movement and the number of days per-week with at least one bowel movement. Plans for naloxegol will be finalized over the coming months, incorporating the outcome of ongoing discussions with health authorities in the US, EU and Canada, the company said. Naloxegol, a peripherally-acting mu-opioid receptor antagonist, has been specifically designed for the treatment of opioid-induced constipation and is part of the exclusive worldwide license agreement announced on 21 September 2009, between AstraZeneca and Nektar Therapeutics (NKTR). |
|
| 09:25 EDT | | MDT | On The Fly: Pre-market Movers
Subscribe for More Information |
|
| 07:34 EDT | | IDIX | UBS to host a conference
Subscribe for More Information |
|
| 07:28 EDT | | PPG | Goldman to host a conference
Subscribe for More Information |
|
| 07:19 EDT |  | MDT | Medtronic sees FY14 EPS $3.80-$3.85, consensus $3.84
Sees FY14 revenue growth up 3%-4% on a constant currency basis. |
|
| 07:17 EDT | | MDT | Medtronic reports Q4 EPS $1.10, consensus $1.03
Subscribe for More Information |
|
| 05:54 EDT | | MDT | Medtronic announces primary results from Global Symplicity Registry
Subscribe for More Information |
|
| 05:51 EDT | | MDT | Medtronic CoreValue ADVANCE study shows low mortality rates
Subscribe for More Information |
| |
|
|
|
|
